UPDATE - Canaccord Genuity Downgraded United Therapeutics (UTHR) to Hold; Sidelined on Uncertainty
Tweet Send to a FriendGet Alerts UTHR Hot Sheet
Price: $67.82 -0.95%
Rating Summary:
3 Buy, 13 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 28 | New: 14
Rating Summary:
3 Buy, 13 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 28 | New: 14
Trade UTHR Now!
UPDATE - Canaccord Genuity downgraded United Therapeutics Corp. (NASDAQ: UTHR) from Buy to Hold, price target lowered from $56 to $44.
Analyst, Salveen Richter, said, "While the company continues to be a solid cash-generation story, it faces the following challenges: 1) generic threats to Remodulin and Adcirca; 2) the uncertainty of oral treprostinil securing FDA approval in a monotherapy setting on its October 27 PDUFA (one positive P3 monotherapy and two failed P3 combination studies); 3) even if approved, the market potential of oral treprostinil is likely to be limited given physicians’ concern on the magnitude of benefit and their preference for combination use; 4) potential competition from ATLN’s macitentan (P3 SERAPHIN data expected in Q2/12; mortality/morbidity); and 4) a lack of near-term value-driving catalysts."
Lowers FY14 GAAP EPS estimate from $4.89 to $4.21.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Salveen Richter, said, "While the company continues to be a solid cash-generation story, it faces the following challenges: 1) generic threats to Remodulin and Adcirca; 2) the uncertainty of oral treprostinil securing FDA approval in a monotherapy setting on its October 27 PDUFA (one positive P3 monotherapy and two failed P3 combination studies); 3) even if approved, the market potential of oral treprostinil is likely to be limited given physicians’ concern on the magnitude of benefit and their preference for combination use; 4) potential competition from ATLN’s macitentan (P3 SERAPHIN data expected in Q2/12; mortality/morbidity); and 4) a lack of near-term value-driving catalysts."
Lowers FY14 GAAP EPS estimate from $4.89 to $4.21.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- KeyBank Upgrades MDC Holdings (MDC); Cuts PulteGroup (PHM) & Ryland Group (RYL)
- Goldman Sachs Downgrades WellCare Health Plans (WCG) to Neutral
- Benchmark Boosts PT on R.R. Donnelley (RRD)
Create E-mail Alert Related Categories
Analyst EPS Change, Analyst EPS View, Analyst PT Change, Downgrades
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
